Novus Cannabis MedPlan Shows Strong Financial Performance in Q3 2025
Update: 2025-12-17
Description
Novus Cannabis MedPlan, traded as Novus Acquisition and Development Corp., demonstrated robust financial performance in Q3 2025 with notable revenue and EBITDA growth. The company's commitment to non-dilutive capital strategy, self-funding market initiatives, and expanding its Provider and Health Plan Network contributed to its success. Novus's focus on maintaining a strong balance sheet, capital structure integrity, and innovative approach in combining online pharmacy prescription drug plans with Savings Accounts and Flexible Spending Accounts sets them apart in the market.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
